首页 | 本学科首页   官方微博 | 高级检索  
检索        

甘氨酸对急性坏死性胰腺炎鼠血和胰腺组织中TNF-α、IL-1β、IL-6、IL-8和IL-10的影响
引用本文:李海军,彭淑牖,刘颖斌,李江涛,许斌,王建伟.甘氨酸对急性坏死性胰腺炎鼠血和胰腺组织中TNF-α、IL-1β、IL-6、IL-8和IL-10的影响[J].中国病理生理杂志,2006,22(2):239-243.
作者姓名:李海军  彭淑牖  刘颖斌  李江涛  许斌  王建伟
作者单位:浙江大学医学院附属第二医院外科, 浙江 杭州 310009
摘    要:目的:探讨甘氨酸对急性坏死性胰腺炎鼠血和胰腺组织中TNF-α、IL-1β、IL-6、IL-8和IL-10的影响。 方法: Wistar大鼠150只,随机分为3组:假手术组(SO)、急性坏死性胰腺炎组(ANP)和急性坏死性胰腺炎+甘氨酸处理组(ANP+Gly), 以牛磺胆酸钠复制急性坏死性胰腺炎大鼠模型, ANP+Gly组大鼠胰管内给予牛磺胆酸钠前10 min静脉给予甘氨酸1 g/kg。观察血和胰腺组织中ET、TNF-α、IL-1β、IL-6、IL-8和IL-10含量变化,同时观察各组大鼠胰腺组织的病理变化、24 h病死率及平均生存时间。 结果: 在0 h、2 h、4 h、8 h和12 h的血和胰腺组织中ET、TNF-α、IL-1β、IL-6、IL-8 和 IL-10水平, ANP组和ANP+Gly组均显著高于SO组(除0 h组及ANP组的IL-10 12 h外) (P<0.01/P<0.05), 且在ANP和ANP+Gly组ET、TNF-α、IL-1β、IL-6和IL-8随病程进展而升高(P<0.05),在ANP组 IL-10水平随病程进展降低(P<0.05),而在ANP+Gly组IL-10水平随病程进展增高(P<0.05)。在相同时段除ET在ANP组和ANP+Gly组无显著差异外(P>0.05), 除0 h组外, TNF-α、IL-1β、IL-6和IL-8水平在ANP组显著高于ANP+Gly组(P<0.01),而 IL-10水平(除0 h和2 h组无差异外)ANP+Gly组显著高于ANP组(P<0.05/0.01)。虽然ANP组和ANP+Gly组大鼠胰腺组织的病理变化无显著差异,但ANP+Gly组大鼠24 h病死率显著低于ANP组(P<0.05),平均生存时间显著延长于ANP组(P<0.05)。 结论: ET、TNF-α、IL-1β、IL-6 、IL-8 和 IL-10参与了大鼠ANP的病理过程,甘氨酸可减少促炎细胞因子TNF-α、IL-1β、IL-6 和IL-8 的产生,上调抗炎细胞因子IL-10的负调控作用,有助于减轻ANP时炎性细胞因子瀑布样级联反应,降低大鼠24 h病死率及延长平均生存时间。

关 键 词:胰腺炎  甘氨酸  肿瘤坏死因子  白细胞介素1  白细胞介素6  白细胞介素8  白细胞介素10  
文章编号:1000-4718(2006)02-0239-05
收稿时间:2004-06-14
修稿时间:2004-06-142004-10-28

Effect of glycine on changes of TNF- α, IL- 1β, IL- 6, IL- 8 and IL- 10 in rat serum and pancreas tissue with acute necrotizing pancreatitis
LI Hai-jun,PENG SHu-you,LIU Ying-bin,LI Jiang-tao,XU Bin,WANG Jian-wei.Effect of glycine on changes of TNF- α, IL- 1β, IL- 6, IL- 8 and IL- 10 in rat serum and pancreas tissue with acute necrotizing pancreatitis[J].Chinese Journal of Pathophysiology,2006,22(2):239-243.
Authors:LI Hai-jun  PENG SHu-you  LIU Ying-bin  LI Jiang-tao  XU Bin  WANG Jian-wei
Institution:Department of General Surgery, Second Affiliated Hospital, Medical College of Zhejiang University, Hangzhou 310009, China
Abstract:AIM: To evaluate the effect of glycine on the changes of TNF-α, IL-1β, IL-6, IL-8 and IL-10 in rat serum and pancreas tissue with acute necrotizing pancreatitis (ANP). METHODS: 150 Wistar rats were randomly divided into sham operation group (SO), ANP group and ANP+glycine group (ANP+Gly). The ANP model was established by retrograde injection of sodium taurocholate into cholangiopancreatic duct. The glycine (1 g/kg) was injected intravenously 10 min before sodium taurocholate injection. The changes of ET, TNF-α, IL-1β, IL-6, IL-8 and IL-10 in serum and pancreas tissue were determined and the pathological study was performed as well. RESULTS: The levels of ET, TNF-α, IL-1β, IL-6, IL-8 and IL-10 in serum and pancreas tissue (except IL-10 at 0 h and 12 h in ANP group) in ANP and ANP+Gly groups were significantly higher than those in SO (except at 0 h) (P<0.01, P<0.05). The levels of ET, TNF-α, IL-1β, IL-6 and IL-8 were significantly increased in iso-group aniso-time, but the levels of IL-10 were significantly decreased in aniso-time of ANP group and significantly increased in aniso-time of ANP+Gly group (except at 0 h) (P<0.05). Although the levels of ET had not significant difference between group ANP and ANP+Gly, the levels of TNF-α, IL-1β, IL-6 and IL-8 in group ANP were significantly higher than that in group ANP+Gly (except at 0 h) (P<0.01). The levels of IL-10 in group ANP+Gly (except at 0 h and 2 h) were significantly higher than that in group ANP (P<0.01). The pathological change in group ANP and ANP+Gly had not significant difference, but at 24 h fatality rates and average survival time in group ANP+Gly were obvious higher than that in group ANP (P<0.05). CONCLUSION: Glycine decreases the production of TNF-α, IL-1β, IL-6 and IL-8 and up-regulates the expression of IL-10, decreases the 24 h fatality rates and improves the average survival time in rats with ANP.
Keywords:Pancreatitis  Glycine  Tumor necrotic factor  Interleukin-1  Interleukin-6  Interleukin-8  Interleukin-10
本文献已被 CNKI 维普 万方数据 等数据库收录!
点击此处可从《中国病理生理杂志》浏览原始摘要信息
点击此处可从《中国病理生理杂志》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号